Background Influenza remains a significant problem in elderly despite widespread
vaccination coverage. This randomized, phase-I study in elderly compared different …

Several approaches are currently being pursued in order to improve the efficacy of influenza
vaccines in elderly individuals and others who have impaired immune responses to …

To determine if newer influenza vaccines can safely improve seroprotection rates of older
adults, we compared three licensed trivalent inactivated vaccines (TIVs) in a randomized …

In the present study we first compare immunogenicity against vaccine and heterologous
circulating A (H1N1) pdm09 strains, tolerability and safety of intradermal Intanza® 15 μg and …

We conducted a randomized, controlled, multicenter, phase II study to evaluate the
immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine …

Background: Aging and immunosenescence lead to a gradual decline in immune responses
in the elderly and the immunogenicity of influenza vaccines in this age group is sub-optimal …

Background Although seasonal influenza vaccine is effective in the elderly, immune
responses to vaccination are lower in the elderly than in younger adults. Strategies to …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Background Recent clinical evidence indicates that an intradermal (ID) delivery of vaccines
confers superior immunogenicity as compared to a standard intramusclular or subcutaneous …

Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal
(ID) vaccination may be a promising alternative to intramuscular (IM) vaccination. Methods …